Loading stock data…
RVTY
$99.09+6.79 (+7.36%)
Pre-Market$99.59+0.50 (+0.50%)· Last close May 6
Revvity, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revvity, Inc. in the Healthcare sector is trading at $99.09. The stock is currently 16% below its 52-week high of $118.30, remaining 5.2% above its 200-day moving average. Technical signals show neutral RSI of 63 and bullish MACD crossover, explaining why RVTY maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$99.09
Potential Downside
59%
Whystock Fair Value$40.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$113.64+14.7%
Range$95.00 – $140.00
Fundamentals
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
45.77
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.13
Div Yield
Strong income play. Yield provides a meaningful total return floor.
30.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.93%
Volume
Today's trading volume
3.01M
Recent News
Revvity, Inc. Q1 2026 Earnings Call Summary
Moby summary of Revvity, Inc.'s Q1 2026 earnings call
Revvity (RVTY) Q1 2026 Earnings Transcript
Prahlad Singh: Thank you, Steve, and good morning, everyone. First, I'm really excited to report that Revvity delivered strong first quarter results with 3% total company organic growth, demonstrating the resilience and strength of our business. The better-than-anticipated revenue and margin performance in the quarter led to our adjusted earnings per share in the quarter being $1.06, which was solidly above the $1.02 to the $1.04 outlook that was implied in our guidance.
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution
Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity Q1 Earnings Call Highlights
Revvity (NYSE:RVTY) reported first-quarter 2026 results that came in ahead of its expectations and outlined a planned divestiture of its immunodiagnostics business in China, a move management said will sharpen the company’s focus and improve growth and profitability metrics going forward. First-qua